Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Eric Van Cutsem(Universitair Ziekenhuis Leuven), G. Bodoky(Unified Szent István and Szent László Hospital), Ramón Salazar(Institut Català d'Oncologia), Paul N. Mainwaring(Australasia Paediatric Endocrine Group), Ilona Kocáková(Masaryk University), Sheryl Koski(AstraZeneca (Australia)), David Cunningham(Royal Marsden NHS Foundation Trust), Christos S. Karapetis(Clínica Alemana), Bijoyesh Mookerjee(Novartis (United States)), Philippe Rougier(Hôpital Ambroise-Paré), Peter Barker(Leiden University Medical Center), Alberto Sobrero(Ospedale Policlinico San Martino), Jane Robertson(Cancer Research UK), Igor Bondarenko(Dnipro State Medical University)
Cited by 210
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k